Joseph Zapolsky III has spent nearly a quarter century helping build Erchonia Corporation into a global leader in low-level laser therapy. As Chief Experience Officer, he now oversees international sales, clinical education, and strategic growth, guiding the expansion of FDA-cleared, non-invasive laser treatments used for pain management, body contouring, and a growing range of medical applications.
Zapolsky’s connection to Erchonia began long before he officially joined the company. He grew up around the founding families and developed close friendships with members of the team while still in school. By the time he entered his early twenties, the company had evolved from its earliest garage-based operations into a growing medical technology business. That was when he first joined the organization, starting with hands-on work assembling the company’s laser systems.
Over the years, he moved through multiple roles across the business, gaining experience in manufacturing, operations, and sales. That long tenure has given him an unusual perspective on how the company evolved from a small startup into a global medical device manufacturer with products now distributed across dozens of countries.
At the center of Erchonia’s technology is a distinctive approach to laser therapy. Unlike many therapeutic lasers that rely on heat to treat tissue, the company’s systems operate through a photochemical reaction that generates no heat. This allows treatments to remain completely non-invasive while still triggering biological responses that can support healing and recovery.
The company initially built its reputation in pain management, conducting clinical studies focused on conditions such as chronic neck and shoulder pain, plantar fasciitis, lower back pain, and post-operative recovery. These early trials helped establish a scientific foundation that would later support expansion into additional medical fields.
One of the company’s most visible breakthroughs came when Erchonia introduced lasers designed for non-invasive fat reduction. Instead of damaging or destroying fat cells, the technology temporarily opens microscopic pores within the cells, allowing stored fatty material to exit while leaving the cell intact. The body then processes and removes those materials naturally through metabolic pathways.
This approach, which preserves the biological functions of fat cells while still supporting body contouring, helped position Erchonia within the rapidly growing aesthetic medicine market. Today, the company’s devices are used in a wide range of settings, including physician offices, medical spas, dermatology clinics, and fitness centers.
From its headquarters in South Carolina, Erchonia has steadily expanded its global reach. Through international offices and distributor networks, the company’s laser systems are now present in 48 countries. That expansion has brought the technology into hospitals, physical therapy centers, and specialized medical practices around the world.
Even with that growth, Zapolsky believes the company is still in an early phase of its broader mission. Erchonia is now exploring new applications in areas such as veterinary medicine and dentistry, two fields where non-invasive treatments could offer meaningful benefits for both patients and practitioners.
In veterinary medicine, the company sees an opportunity to apply technologies already validated through decades of human clinical research. Treatments that support wound healing, reduce inflammation, or assist with post-operative care could translate effectively into animal health, where reliable therapeutic options are often limited.
Dentistry represents another promising frontier. Early studies are examining the role of low-level laser therapy in addressing gum recession, managing temporomandibular joint discomfort, and supporting recovery following dental procedures. Because dentists routinely perform minor surgical interventions, technologies that help reduce post-procedure pain and accelerate healing may become valuable additions to clinical workflows.
Erchonia’s origins trace back to a practical engineering insight. One of the company’s founders, Kevin Tusek, worked with a physician who used large European laser systems to treat chronic pain. Recognizing that the equipment was bulky and difficult to maintain, he set out to design a smaller, more efficient alternative that could be manufactured domestically.
That effort led to the creation of Erchonia’s first laser system, initially built in a garage workshop and sold to physicians who quickly saw its potential. From those early prototypes, the company grew steadily, fueled by clinical research, regulatory approvals, and adoption among healthcare providers.
Now celebrating three decades in operation, Erchonia has evolved into a company whose technology is used across tens of thousands of clinical settings worldwide. For Zapolsky, the journey from part-time assembly work to executive leadership reflects more than career growth. It represents a long-term commitment to a technology he believes can continue reshaping how medicine approaches pain, recovery, and non-invasive treatment.
As the company prepares to introduce new products and expand further into international markets, Zapolsky sees the next chapter of Erchonia’s story as one defined by continued research, education, and global adoption of laser therapies that prioritize safety alongside effectiveness.
Want more Innovation Saves Lives? Check out the articles or head over to Apple Podcasts.
